Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development and Biomarker Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Septin 9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Septin 9 Recombinant Protein (Full-length / Specific Splice Variants) High purity (>90%), Endotoxin Controlled, Sequence Verified, Theoretical MW confirmed. |
View Septin 9 Products |
| Gene Delivery | Septin 9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and intracellular localization assays. |
View Septin 9 Products |
| Benchmark Ab | Anti-Septin 9 Recombinant Antibody Sequence-derived monoclonal positive control for IHC, Western Blot, and ELISA. |
View Septin 9 Products |
| Validator | Septin 9 siRNA Set Target-specific knockdown verification in functional tumor assays. |
View Septin 9 Products |
| Related Target A | SEPT2 Essential partner in the octameric septin complex (SEPT2-SEPT6-SEPT7-SEPT9) required for filament assembly. |
View SEPT2 Products |
| Related Target B | SEPT7 The core scaffolding subunit of the septin complex; critical counter-screening target for selectivity. |
View SEPT7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Splice Variant Specificity (e.g., SEPT9_v1 vs v3) | Isoform-specific recombinant proteins strictly sequence-verified by MS/MS. |
| Filament Assembly Inhibition Screening | High-purity, monomeric Septin proteins to minimize baseline aggregation in turbidimetric assays. |
| Lack of Validated Controls | Recombinant benchmark antibodies with published sequence fidelity. |
| Off-Target Cytotoxicity Validation | Sequence-specific siRNA pools for target validation and rescue assays. |
Live Septin 9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Septin 9 therapeutics is intensifying, with major players shifting focus from traditional diagnostic biomarker applications (such as DNA methylation assays for early colorectal cancer detection) to targeted therapeutic intervention in solid tumors. As the role of Septin 9 in microtubule stabilization, cytokinesis, and chemotherapy resistance (particularly to taxanes) becomes clearer, the next wave of R&D is targeting the protein-protein interactions (PPI) within the septin oligomer or the GTPase domain using small-molecule inhibitors and PROTACs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GTPase / PPI Inhibitors) | Academic institutions, Emerging Biotechs | Breast Cancer, Prostate Cancer, Colorectal Cancer | Filament Polymerization Assay (Requires monomeric, high-purity SEPT9 & SEPT7 proteins) |
| RNA Therapeutics (siRNA/ASO) | Preclinical Stage Biopharma | Taxane-resistant Solid Tumors | Stable cell line generation (Need high-titer Lentivirus for rescue/overexpression studies) |
| Diagnostic Antibodies (IHC / Liquid Biopsy) | In Vitro Diagnostic (IVD) Companies | Early CRC Detection, Pan-cancer Screening | High-affinity Recombinant Antigens (HEK293 or E. coli expressed with precise sequence verification) |